Daily Stock Analysis, AMAG, AMAG Pharmaceuticals Inc, priceseries

AMAG Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
17.85
Close
18.50
High
18.55
Low
17.60
Previous Close
17.90
Daily Price Gain
0.60
YTD High
18.60
YTD High Date
Feb 15, 2018
YTD Low
11.95
YTD Low Date
Feb 9, 2018
YTD Price Change
3.90
YTD Gain
26.71%
52 Week High
25.20
52 Week High Date
Mar 8, 2017
52 Week Low
11.93
52 Week Low Date
Nov 2, 2017
52 Week Price Change
-5.65
52 Week Gain
-23.40%
Company Information
Stock Symbol
AMAG
Exchange
NasdaqGS
Company URL
http://www.amagpharma.com
Company Phone
6174983300
CEO
William K. Heiden
Headquarters
Massachusetts
Business Address
1100 WINTER STREET, WALTHAM, MA 02451
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
0000792977
About

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron deficiency anemia or IDA. The company engages in manufacture, development and commercialization of products derived from its proprietary technology for use in treating human diseases. The company was founded on 9th, November 1981 and is headquartered in Waltham, MA.

Description

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.